Skip to main content

Table 2 Comparisons of clinical characteristics among different groups

From: Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study

   Total
n = 17 (%)
Adjuvant Group
n = 5 (%)
Palliative Group
n = 6 (%)
Control Group
n = 6 (%)
P value
Age (Mean ± SD) 55.6 ± 8.6 53.4 ± 4.7 60.0 ± 12.5 53.2 ± 5.1 0.324
Sex      0.133
   F 4 (23.5) 0 (0) 1 (16.7) 3 (50.0)  
   M 13 (76.5) 5 (100.0) 5 (83.3) 3 (50.0)  
Viral Hepatitis      0.135
   HBV 11 (64.7) 4 (80.0) 5 (83.3) 2 (33.3)  
   HCV 6 (35.3) 1 (20.0) 1 (16.7) 4 (66.7)  
C-P Classification      0.522
   A 10 (58.8) 4 (80.0) 2 (33.3) 4 (66.7)  
   B 4 (23.5) 1 (20.0) 2 (33.3) 1 (16.7)  
   C 3 (17.6) 0 (0) 2 (33.3) 1 (16.7)  
Pre-OLT BCLC Staging      0.011
   A 1 (5.9) 1 (20.0) 0 (0) 0 (0)  
   B 6 (35.3) 4 (80.0) 1 (16.7) 1 (16.7)  
   C 7 (41.2) 0 (0) 2 (33.3) 5 (83.3)  
   D 3 (17.6) 0 (0) 3 (50.0) 0 (0.0)  
Donor Type      0.624
   CD 15 (88.2) 5 (100) 5 (83.3) 5 (83.3)  
   LD 2 (11.8) 0 (0) 1 (16.7) 1 (16.7)  
1 st Relapse Site      0.052
   Liver 6 (35.3) 1 (20.0) 2 (33.3) 3 (50.0)  
   Lung 4 (23.5) 0 (0) 2 (33.3) 2 (33.3)  
   Portal vein 2 (11.8) 0 (0) 2 (33.3) 0 (0.0)  
   No relapse 5 (29.4) 4 (80.0) 0 (0) 1 (16.7)  
  1. SD: standard deviation, F: female, M: male, HBV: hepatitis B virus, HCV: hepatitis C virus, C-P: Child-Pugh, OLT: orthotopic liver transplantation, BCLC: Barcelona Clinic Liver Cancer, CD: cadaveric donor, LD: living donor